Promising industries and companies operating in them could suffer setbacks during situations such as the global COVID-19 pandemic. That’s a lesson to learn in online trading. But these setbacks can be overcome if these companies have significant long-term potential.

Impinj ($PI)
The radio-frequency and wireless tech provider Impinj was affected by the pandemic like many industries were. Here’s how it performed in the four quarters of a loss-making 2020:

  • For Q1 2020, Impinj earned revenue worth $47.8 million. It also made GAAP net loss worth $4.3 million.   
  • The company admitted that COVID-19 had a negative impact on its Q2 2020 financial results. It reported revenue worth $26.5 million, significantly lesser than its Q1 revenue. Its GAAP net loss was also greater, at $17.5 million.
  • For Q3 2020, Impinj reported revenue worth $28.2 million, which beat the stock market’s expectations and was a slight growth from Q2 though it was a year-over-year drop of 30%.
  • During Q4 2020, Impinj managed to earn $36.4 million worth of revenue. It also reported GAAP net loss worth $15.7 million.

Ocugen ($OCGN)
The pandemic did bring about challenges for the biotech company Ocugen that focuses on treating blindness-related diseases, but it could still complete the planned enrolment of its OCU300 drug for treating ocular graft versus host disease during Q1.

  • For Q1 2020, Ocugen reported a net loss worth $3.9 million. This was less than the $6.3 million net loss sustained in Q1 2019. Cash and cash equivalents, as well as restricted cash, amounted to $3.3 million, compared to Q1 2019’s $7.6 million.
  • For Q2 2020, the company reported a net loss worth $3.6 million, more than the net loss worth $3.5 million it sustained in Q2 2019. Cash and cash equivalents, as well as restricted cash, amounted to $15.1 million.
  • For Q3 2020, Ocugen reported cash & cash equivalents as well as restricted cash totaling $19.3 million. Loss per share was reported at $0.07 per share, significantly lesser than the $3.35 loss per share sustained in Q3 2019.
  • Q4 2020 saw Covaxin, the COVID-19 vaccine candidate Ocugen is hoping to bring to the US market from India, demonstrate 81% efficacy in interim Phase 3 results. For the full 2020, Ocugen reported cash & cash equivalents as well as restricted cash totaling $24.2 million. This was more than $7.6 million as of December 31, 2019. Full-year net loss per share was reported at $0.31, compared to $1.46 by December 31, 2019. 

Nikola ($NKLA)
The fuel-cell truck designer and manufacturer is a start-up having to promise alternatively powered truck models with the potential to disrupt the market. However, being a start-up, it is going through the initial loss-making stage. Add COVID-19 to the equation, and the company had a challenging 2020 on its hands.  

  • For Q2 2020 Nikola reported a net loss worth $86,643 compared to $16,766 for Q2 2019.
  • For Q3 2020 Nikola reported a net loss of $117,469 compared to $15,514 for Q3 2019.
  • Q4 2020 saw Nikola reporting a net loss worth $147,096 compared to $26,279 for Q4 2019.

Visa ($V)
For the credit card company Visa, the rise in online payments did give the company year-over-year revenue growth from 2019. However, the company’s business drivers experienced a slowdown in growth, particularly in Q2.  

  • During Q1 2020, Visa earned net revenue worth $6.1 billion. This was a year-over-year growth of 10%.  
  • For Q2 2020, the company reported net revenue worth $5.9 billion, a year-over-year growth of 7%.
  • Q3 2020 saw Visa attain net operating revenue worth $4.8 billion. While this overtook the estimates by Zacks by 0.62%, the company reported a year-over-year drop of 17% in the top line.   
  • The fourth quarter of 2020 saw the company report net revenue worth $5.1 billion, a 17% decline.

This quarterly data from companies representing various industries can give you an idea of temporary setbacks for these stocks and prospects in the future. Such data is important along with advanced trading platforms.  

 

DISCLAIMER
The content of this message and its attachments are intended only for the informational and educational use for the intended recipient and may contain confidential and privileged information. If you are not the intended recipient, any dissemination, distribution, or copying of this message or its attachments is prohibited. If you received this message in error, please notify the sender by replying to this email immediately and delete this message and its attachments from your computer. This content does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by the writer or company employing the writer in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. All communications sent to or from TradeZero, Inc. are subject to archive and review by TradeZero, Inc. and by regulatory and law enforcement authorities. We explicitly disclaim all liability for any action taken based on any information contained in this writing.